Daily Respiratory Research Analysis
Analyzed 105 papers and selected 3 impactful papers.
Summary
Analyzed 105 papers and selected 3 impactful articles.
Selected Articles
1. Multi-omics biomarkers of endothelial dysregulation preceding chronic lung allograft dysfunction: A prospective cohort study.
Longitudinal multi-omics profiling of BAL fluid up to 30 months post-transplant identified a pre-CLAD signature marked by increased sphingolipids and upregulation of endothelial glycocalyx and immune cell recruitment genes expressed by monocytes, endothelial, and T cells. This signature persisted beyond 1.5 months post-transplant in patients who later developed CLAD and intensified at lung function decline.
Impact: Provides an integrative systems-level framework and candidate biomarkers for earlier CLAD detection, addressing a major unmet need in lung transplantation.
Clinical Implications: Suggests monitoring sphingolipids and endothelial glycocalyx/immune-recruitment transcripts in BAL as early warning signals, potentially enabling preemptive interventions before irreversible allograft damage.
Key Findings
- Early post-transplant period in CLAD-free patients showed reduced microbial diversity with increased Staphylococcus/Candida and heightened innate/adaptive responses, then a shift to tissue repair with T-cell gene reactivation after immunosuppression taper (FDR<0.05).
- In patients who developed CLAD, pre-onset BALs had elevated sphingolipids and upregulated glycocalyx and immune-recruitment genes (e.g., HAPLN3, HS3ST3B1, SULF2, CHST2, CXCR1, CSF3R, SELL, CXCL2, CEACAM1; FDR<0.05).
- Single-cell mapping attributed the transcriptomic signature to monocytes, endothelial cells, and T cells; the signature persisted beyond 1.5 months and intensified with spirometric decline.
- Multi-omics integration highlighted endothelial function and immune-recruitment pathways as candidate biomarkers for CLAD onset; findings are associative and require validation.
Methodological Strengths
- Prospective longitudinal design with multi-omics integration (microbiome, metabolomics, lipidomics, transcriptomics) of serial BAL samples.
- Rigorous statistical control (FDR) and orthogonal validation using public single-cell datasets to assign cellular sources.
Limitations
- Small sample size and hypothesis-generating nature limit causal inference and generalizability.
- Biomarkers identified in BAL may be challenging to implement clinically without targeted, validated assays.
Future Directions: Conduct targeted validation (e.g., qPCR, targeted MS) in independent cohorts; evaluate less invasive biospecimens; test whether modulating endothelial glycocalyx pathways alters CLAD risk.
BACKGROUND: Long-term survival of lung transplant recipients remains limited by chronic lung allograft dysfunction (CLAD). CLAD is only diagnosed following a persistent and substantial decline in lung function, after which irreversible damage to the lungs has occurred, limiting opportunities to effectively intervene at an early stage. There is a critical need for earlier detection prior to its clinical manifestation. The immunological drivers of CLAD remain unclear, limiting the development of predictive biomark
2. Interim Estimated Effectiveness of 2025-2026 COVID-19 Vaccines in Adults Using a Test-Negative Design.
Across 85,725 ED/UC encounters and 26,073 hospitalizations, receipt of a 2025–2026 JN.1-based COVID-19 vaccine was associated with 50% effectiveness against ED/UC visits and 55% effectiveness against hospitalization. Protection persisted among adults ≥65 years, indicating meaningful incremental benefit over background immunity.
Impact: Provides timely, real-world vaccine effectiveness estimates for an updated formulation against circulating JN.1 sublineages, directly informing seasonal vaccination policy and risk communication.
Clinical Implications: Supports recommending 2025–2026 vaccination to reduce medically attended COVID-19, including in older adults; reinforces prioritization of timely boosters as variants evolve.
Key Findings
- Vaccine effectiveness against ED/UC encounters was 50% (95% CI, 42–57%) at a median 47 days post-dose.
- Vaccine effectiveness against hospitalization was 55% (95% CI, 41–66%) at a median 46 days post-dose.
- Among adults ≥65 years, VE was 48% for ED/UC and 53% for hospitalization, indicating benefit in higher-risk groups.
- Findings suggest added protection from 2025–2026 vaccination beyond existing immunity from prior infection and vaccination.
Methodological Strengths
- Large, multi-state electronic health record network using a validated test-negative design.
- Adjusted analyses accounting for key confounders and stratification by age group.
Limitations
- Short interim time window limits assessment of durability and variant-specific waning.
- Residual confounding and misclassification (e.g., prior infections, testing behavior) cannot be fully excluded.
Future Directions: Evaluate durability and waning across sublineages, booster timing optimization, and VE against severe outcomes including ICU admission and death.
IMPORTANCE: The 2025-2026 COVID-19 vaccine, targeting JN.1 and JN.1-derived sublineages, became available in the US in September 2025. OBJECTIVE: To assess the estimated interim effectiveness of 2025-2026 COVID-19 vaccines against medically attended COVID-19 among immunocompetent adults aged 18 years or older in the US. DESIGN, SETTING, AND PARTICIPANTS: This case-control study used a test-negative design to investigate patient encounters captured in the Virtual SARS-CoV-2, Influenz
3. Hypoxic Burden Correlates with Blood Pressure Rhythm in Obstructive Sleep Apnea.
In 377 patients undergoing PSG and 24‑hour ABPM, higher hypoxic burden was independently associated with systolic non-dipping and nocturnal hypertension, whereas traditional hypoxic indices did not show consistent associations after adjustment. HB may better capture clinically relevant OSA-related hypoxemia.
Impact: Refines OSA phenotyping by validating hypoxic burden as a superior hypoxemia metric linked to adverse BP rhythms, with implications for cardiovascular risk stratification.
Clinical Implications: Incorporating hypoxic burden into PSG reports could enhance identification of patients at risk for nocturnal hypertension and guide earlier antihypertensive or OSA-targeted interventions.
Key Findings
- Hypoxic burden was significantly higher in non-dipper vs dipper groups and remained associated with systolic non-dipping after multivariable adjustment.
- HB was independently associated with nocturnal hypertension; conventional PSG hypoxic metrics failed to show consistent adjusted associations.
- Quartile analyses showed patients in the highest HB quartile had the greatest odds of BP rhythm impairment.
Methodological Strengths
- Objective pairing of full polysomnography with 24‑hour ambulatory BP monitoring.
- Multivariable models adjusting for a broad set of confounders and quartile-based analyses.
Limitations
- Observational cross-sectional design precludes causal inference and temporal sequencing.
- Generalizability may be limited by single-center setting and suspected OSA referral population.
Future Directions: Prospective studies to test whether HB-guided therapy reduces nocturnal hypertension and cardiovascular events; standardize HB computation across PSG systems.
STUDY OBJECTIVES: Obstructive sleep apnea (OSA) is associated with disturbances in blood pressure (BP) patterns, which is recognized as an independent cardiovascular risk factor. However, conventional hypoxic indicators of OSA severity showed inconsistent associations with these BP disturbances. Hypoxic burden (HB), a metric integrating the frequency, depth, and duration of desaturation, may better represent the characteristics of hypoxia. We hypothesized that HB would be more closely associated with BP pat